Preston Noon

Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA.

Citigroup Global Markets Holdings, Inc. provides investment banking and securities brokerage services. It offers financial advisory, research and capital raising services to corporations, governments and individuals. The company was founded in 1977 and is headquartered in New York, NY.

Cempra Pharmaceuticals, Inc. develops medicines for treating drug-resistant bacterial infections. The firm's antibacterial products, both in clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community. The company was founded by Prabhavathi B. Fernandes IN 2006 and is headquartered in Chapel Hill, NC.

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Gliknik, Inc. discovers and develops biotechnology drugs for autoimmune diseases and cancer. The company was founded by David S. Block and Scott E. Strome in 2007 and is headquartered in Baltimore, MD.

Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL.

Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA.

JPMorgan Chase & Co. (Investment Management) (JPM-IM) is the investment management division of JPMorgan Chase & Co. (NYSE: JPM), a multinational investment bank and financial services holding company headquartered in New York City. JPM-IM offers investment solutions to individuals, corporations, governments and institutions.

Cross Atlantic Capital Partners LLC (Cross Atlantic Capital) is a venture capital firm founded in 1999 by Donald Caldwell and Gerry McCrory. The firm is headquartered in Radnor, Pennsylvania with an additional offices in the United Kingdom and Israel.

Protez Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It develops antibiotics for infections & provides research service on intravenous & oral small molecule antibiotics to chronic and recurrent infections. The company was founded by Klaus Esser, Luigi Xerri & Christopher M. Cashman in 2003 and is headquartered in Malvern, PA.

Acorn Performance Group, Inc. engages in the provision of profitability and cost management software solutions. It offers process modeling, data integration, calculation engine, and reporting into a solution for guiding a business. The firm serves the automotive, banking, chemical, consumer products, distribution, education, financial services, healthcare, information technology, insurance, manufacturing, retail, transportation and logistics, and utilities sectors. The company was founded by Steven R. Anderson and Jim Brigman on July 6, 2001 and is headquartered in Austin, TX.

Federated Co-Operatives Ltd. distributes feed plants, grocery supplies and propane. It provides wholesale, manufacturing and administrative services to retail co-operatives. Federated Co-Operatives was established in 1928 and is headquartered in Saskatoon, Canada.

Baxter BioScience Corp. provides biopharmaceutical and vaccines services. It offers a portfolio of therapeutic proteins derived from either human plasma or recombinant technology. The company is headquartered in Beltsville, MD.

Illinois Biotechnology Industry Organization, also known as ibio, is a state trade association representing the life sciences industry in Illinois. The non-profit company is based in Chicago, IL. The organization's mission is to promote, connect, and engage the life sciences community to drive discovery, transform lives through groundbreaking research, and grow the economy. The company's membership ranges from corporations to startup companies in the biopharma, medical device, and nutrition industries. The Illinois life sciences industry is recognized as a national leader, and ibio's members are committed to expanding the boundaries of science by discovering, developing, and delivering innovative and needed therapeutics and products to transform patients' lives.

Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland.

Corridor Pharmaceuticals, Inc. develops and manufactures biopharmaceutical products. The company was founded on February 1, 2008 and is headquartered in Lutherville, MD

Baxter Ventures (Baxter Ventures) is a venture capital firm subsidiary of Baxter International, Inc. founded in 2011. The firm is headquartered in Deerfield, Illinois.

Invisible Sentinel, Inc. engages in food diagnostics. It offers food safety, wine, beer products such as veriflow for salmonella, listerria species and vinoBrett for breetanomyces bruxellensis, vinoPAL for pedicoccus and lactobacillus and veriflow custom solutions. The company was founded by Nicholas Siciliano and Benjamin Pascal in October 2006 and is headquartered in Philadelphia, PA.

Bamboo Therapeutics, Inc. develops gene therapy products for central nervous system and neuromuscular diseases. Its therapeutic platform is based on the use of Adeno-associated virus as a gene therapy vehicle. The company’s proprietary technologies include chimeric vectors, self-complementary vectors, and dual glycan receptor. It focuses on the treatment of Duchenne muscular dystrophy, giant axonal neuropathy, Friedreich ataxia, and Canavan disease. Bamboo Therapeutics was founded by Richard Jude Samulski, Sheila A. Mikhail, Josh Grieger, Xiao Xiao, and Paola Leone in December 2014 and is headquartered in Chapel Hill, NC.

Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands.

Triumvira Immunologics, Inc. develops and manufactures pharmaceutical products. The company was founded by Jonathan Bramson in 2015 and is headquartered in Hamilton, Canada.

Histide AG operates as a biotech intellectual property platform for non-mutagenic extracellular therapeutic agents. The company was founded by Omar F. Zouani , Benoît Lienard and Veronika Gocheva in 2014 and is headquartered in Schindellegi, Switzerland.

Immunitas Therapeutics, Inc. provides cancer therapeutics services. The company was founded by Lea Hachigian, Kai Wucherpfennig, K. Dane Wittrup and Mario Suv? and is headquartered in Cambridge, MA.

Interius BioTherapeutics, Inc. is a biopharmaceutical company that targets cancer. The company was founded by Saar Gill and is headquartered in Philadelphia, PA.

Carbon Biosciences, Inc. is a biotech company that is based in Boston, MA. The company is focused on expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues and carry a larger cargo with minimal neutralizing immunity and the potential to re-dose. The company is working to expand the gene therapy toolbox for the treatment of the world's most devastating and difficult to treat diseases. Carbon was founded by Longwood Fund and gene therapy pioneers, John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D.

Pheast Therapeutics Inc is a pre-clinical stage immuno-oncology company that focuses on targeting cancer immune evasion pathways to activate the innate immune system in the fight against cancer. The company is based in Palo Alto, CA. Pheast aims to develop novel therapies for some of the most difficult-to-treat and aggressive cancers, as well as women's cancers including ovarian cancer and breast cancer. The company was founded in 2020 and is led by scientific experts in innate immunity and cancer immunotherapy. Jacopo Leonardi has been the CEO of the company since 2023.

Pathway To Cures (Pathway To Cures) is a venture capital firm founded in 2022. The firm is headquartered in New York.

Zenas Pharma, Inc. is an American pharmaceutical company that is focused on developing a portfolio of first- and autoimmune therapeutics to address areas of high unmet medical need. The company is located in the US. The company's lead product candidate, obexelimab (zb012), is a novel bifunctional antibody with first-in-class potential that inhibits B-cell lineages that express CD19.

True North Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class product candidates for complement-mediated diseases. The company was founded by Nancy E. Stagliano in 2013 and is headquartered in South San Francisco, CA.